

**4<sup>th</sup> HEPATITIS C**  
TECHNICAL ADVISORY  
GROUP  
**TAG Meeting**

**LONG-TERM HEALTH OUTCOME AMONG  
HCV PATIENTS WITH ADVANCED LIVER  
FIBROSIS TREATED THROUGH THE HCV  
ELIMINATION PROGRAM**

Maia Kajaia, MD, MS  
Health Research Union



სანმრთალობის კვლევის კავშირი

# Goal

- **Evaluation of long-term treatment outcome among patients with advanced liver fibrosis treated with DAAs after achieving sustained viral response (SVR)**

# Objectives

Recruit and follow a cohort of HCV-infected persons with advanced liver fibrosis enrolled in HCV Elimination Program to estimate:

- Changes in liver fibrosis level;
- Changes in liver enzymes and platelets;
- The risk of decompensated liver cirrhosis.

# Participating clinics

- Neolab
- Infectious diseases clinic
- Hepa
- Mrcheveli



# Methods

- Study cohort included patients who:
  - completed full course of the DAA treatment through HCV elimination program in Georgia
  - had advanced liver fibrosis level by elastography ( $\geq$ F3) or FIB4 score ( $\geq$ 3.25)
  - achieved SVR at week 12-24 post treatment

# Methods

- Study cohort selected from patients enrolled in HCV elimination program in May-December, 2015;
- Follow-up visits performed in Nov/2017 – Jun/2018 (~2 years after SVR achieved)
- Baseline data: extracted from medical records
- Follow-up data: prospectively collected

# Methods

- Baseline and post treatment changes were evaluated:
  - Liver fibrosis level (in kpa or FIB4 score)
  - ALT
  - AST
  - PLTs
  - Spleen size
  - Presence of ascites

# Results

Totally 600 patients were enrolled (150 patients from each clinic)

## Demographic characteristics of the sample

Characteristic	N	%
<b>Age</b>		
18 – 49	250	41.7
≥ 50	350	58.3
<b>Gender</b>		
Female	85	14.2
Male	515	85.8



# Results

## Baseline clinical characteristics of the sample

Characteristic	N	%
<b>Liver fibrosis</b>		
F3	80	13.3
F4	450	75.0
<b>Ascites</b>		
Present	12	2.0
Not present	586	97.7


# Results

## Baseline clinical characteristics of the sample

Characteristic	Mean
FIB4 score	3.52
ALT	111.55 u/ml
AST	89.75 u/ml
HB	14.79 g/dL
PLTs	159 10 <sup>9</sup> /L
Spleen size	136X56 mm


# Results

## Changes in mean liver fibrosis level




# Results

## Changes in mean serum ALT and AST levels




# Results

## Changes in mean PLT count and HB level




# Results

## Changes in mean spleen size



# Results



# Conclusion

- Significant improvement in liver fibrosis level and different clinical and laboratory measures was observed 2 years after achieving SVR among patients with advanced liver fibrosis treated with DAAs through HCV elimination program.



# Next steps

- Estimate the risk of HCC development
- Estimate lethal outcomes (extract information from national database)
- Follow-up investigations at year 3, 4 and 5 post treatment (if funding will be available)

**4<sup>th</sup> HEPATITIS C**  
TECHNICAL ADVISORY  
GROUP  
**TAG Meeting**

**THANK YOU !!!**